Change in Boardroom
| PHARMANIAGA BERHAD |
| Date of change | 20 Jul 2022 |
| Name | DR MARY JANE CARDOSA |
| Age | 70 |
| Gender | Female |
| Nationality | Malaysia |
| Designation | Director |
| Directorate | Independent and Non Executive |
| Type of change | Appointment |
Qualifications
| No | Qualifications |
Major/Field of Study |
Institute/University |
Additional Information |
|
Doctorate
|
Doctor of Philosophy |
University of Oxford, England |
|
|
|
Masters
|
Master of Arts |
Columbia University, New York, United States |
|
|
|
Degree
|
Bachelor of Arts |
Princeton University, New Jersey, United States |
|
| Working experience and occupation | Present - Chief Technical Officer of Integrated Research Associates LLC, Founder and Director of MAB Explorations Sdn Bhd and Founder and Director of Venture Technologies Sdn Bhd 2009 to 2018 - Founder and Chief Scientific Officer of Sentinext Therapeutics Sdn Bhd 1995 to 2010 - Founding Director of Institute of Health and Community Medicine of the Universiti Sarawak Malaysia 1994 to 1995 - Associate Professor at the School of Pharmaceutical Sciences, Universiti Sains Malaysia 1990 to 1994 - Lecturer at the School of Pharmaceutical Sciences, Universiti Sains Malaysia 1985 to 1989 - Lecturer at the School of Medical Sciences, Universiti Sains Malaysia Jan to Apr 1985 - Postdoctoral Fellow at the Research Institute of the Scripps Clinic, La Jolla, C.A, USA 1980 to 1984 - Research Assistant on a Welcome Trust Grant at the Dunn School of Pathology of the University of Oxford, U.K |
| Directorships in public companies and listed issuers (if any) | NIL |
| Family relationship with any director and/or major shareholder of the listed issuer | NIL |
| Any conflict of interests that he/she has with the listed issuer | NIL |
| Details of any interest in the securities of the listed issuer or its subsidiaries | NIL |
Announcement Info
| Company Name | PHARMANIAGA BERHAD |
| Stock Name | PHARMA |
| Date Announced | 20 Jul 2022 |
| Category | Change in Boardroom |
| Reference Number | C03-13072022-00007 |